December 13, 2016
Biogen Japan said on December 12 that it has filed a new drug application in Japan for nusinersen sodium, an investigational drug for the treatment of spinal muscular atrophy (SMA). If approved, nusinersen will be Japan’s first antisense drug. Nusinersen...read more